Provides Latest News About Over-the-Counter Alli, Low-Dose Xenical

Share Article, an independent news site published by Medical Week News, Inc., provides the latest news about Alli, trade name for low-dose Xenical. Alli, which is half the strength of prescription Xenical (orlistat), is seeking approval to become the first prescription weight-loss drug to be sold over-the-counter. Medical Week News also publishes the highly rated site,, reporting on the new prescription weight-loss drug, Acomplia (rimonabant).

Medical Week News, Inc., publisher of the highly rated Acomplia Report (, announced it has launched a new guide to weight-loss drugs called Alli Report ( to cover latest news about the new over-the-counter version of the prescription weight-loss medication Xenical (orlistat).

“With Alli awaiting U.S. Food and Drug Administration (FDA) approval to be sold without a prescription, we believe a growing number of Americans will soon be searching for independent, objective news and information about the benefits and risks of taking this low-dose version of Xenical,” said Milton R. Benjamin, publisher of Alli Report (

“We intend to provide all the positive and negative expert opinions on the use of Alli just as our other obesity publication, Acomplia Report (, provides all the news about the prescription drug rimonabant as it makes its way through the FDA and European approval processes,” Benjamin added.

The Alli Report ( will be updated daily by Medical Week News, and will keep readers fully informed on the FDA approval process, and when this over-the-counter version of low-dose Xenical will be available to the public.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Milton Benjamin
Visit website